{
  "Study_ID": "Kaur_2010",
  "First_Author": "Kaur, Prabhjeet",
  "Year": "2010",
  "Country": "India",
  "Study_Design": "RCT",
  "Risk_of_Bias": "Moderate",
  "Diagnostic_Criteria": "SSECTL com critérios de imagem definidos",
  "Total_Sample_Size": "120",
  "Treatment_Group_N": "58",
  "Control_Group_N": "62",
  "Age_Mean_SD": "1-12",
  "Male_Percentage": "",
  "Female_Percentage": "",
  "Single_Lesion_N": "120",
  "Multiple_Lesions_N": "0",
  "Lesions_Mean_Number": "1",
  "Parenchymal_Location_%": "100",
  "Extraparenchymal_%": "0",
  "Active_Cysts_%": "100",
  "Calcified_Lesions_%": "0",
  "Focal_Seizures_%": "",
  "Generalized_Seizures_%": "",
  "Headache_%": "",
  "Other_Symptoms": "Primeira crise convulsiva",
  "Treatment_Type": "Albendazole",
  "Albendazole_Dose": "15 mg/kg/dia",
  "Praziquantel_Dose": "",
  "Treatment_Duration_Days": "7 vs 28",
  "Number_of_Cycles": "1",
  "Cycle_Interval_Days": "",
  "Corticosteroid_Type": "Prednisolona",
  "Corticosteroid_Dose": "2 mg/kg/dia",
  "Corticosteroid_Duration": "7",
  "Antiepileptic_Drug": "Sim",
  "AED_Dose": "",
  "Follow_up_Duration_Months": "6",
  "Lost_to_Follow_up_N": "9",
  "Imaging_Schedule": "TC aos 3 e 6 meses",
  "Complete_Resolution_%": "63.8 (A) / 51.6 (B)",
  "Partial_Resolution_%": "",
  "No_Change_%": "",
  "Calcification_Rate_%": "19.0 (A) / 24.2 (B)",
  "Seizure_Free_%": "90.4 (A) / 96.6 (B)",
  "Seizure_Reduction_%": "",
  "EITB_Positive_%": "",
  "ELISA_Positive_%": "",
  "CSF_Analysis": "Realizado mas resultados não reportados",
  "Elevated_Liver_Enzymes_%": "",
  "Total_AE_N": "3",
  "Headache_AE_%": "",
  "Seizures_AE_%": "9.6 (A) / 3.4 (B)",
  "Gastrointestinal_AE_%": "",
  "Other_AE": "Rash cutâneo e Síndrome de Stevens-Johnson (anticonvulsivantes)",
  "Comments": "Estudo randomizado comparando 1 vs 4 semanas de albendazol em crianças com SSECTL. Não houve diferença significativa na resolução completa das lesões (63.8% vs 51.6%) ou na taxa de calcificação (19% vs 24.2%). A recorrência de crises foi similar (9.6% vs 3.4%, p>0.05). A maioria das resoluções ocorreu nos primeiros 3 meses. Eventos adversos foram relacionados aos anticonvulsivantes, não ao albendazol."
}
